Tinnitus May Signal Inherited Hearing Loss Gene, Chinese Study Finds

A ringing in the ears that arrives years before any measurable hearing loss could be one of the earliest warning signs of a specific inherited form of deafness, according to a new study of Chinese families published in the Journal of Translational Medicine. Researchers led by Qiujing Zhang and Qiuju Wang of the First Medical Center of Chinese PLA General Hospital, together with colleagues at Tongji Hospital and West China Hospital of Sichuan University, found that variants in a single gene, POU4F3, accounted for roughly one in ten families in their referral cohort of autosomal dominant non-syndromic hearing loss, a proportion notably higher than figures reported in comparable European, Japanese, and Korean cohorts.

The gene at the center of the study, POU4F3, sits on chromosome 5 and encodes a transcription factor known as Brn-3c, a protein that acts as a master switch for the survival and function of hair cells, the delicate sensory receptors inside the cochlea that convert sound vibrations into electrical signals for the brain. Because hair cells do not regenerate in humans, any genetic insult that compromises their maintenance translates into progressive, irreversible sensorineural hearing loss. The gene was first linked to inherited deafness through the DFNA15 locus, and since then a growing catalogue of pathogenic variants has been assembled worldwide, though its mutational landscape in Chinese populations had remained incompletely charted until now.

To fill that gap, the team evaluated 83 unrelated families diagnosed with autosomal dominant non-syndromic hearing loss at two tertiary referral centers in China. Each family underwent whole-exome sequencing, a technique that reads the protein-coding regions of the genome and allows researchers to sift through tens of thousands of variants in search of the causal culprit. Candidate variants in POU4F3 were then validated by Sanger sequencing, the classical gold-standard method, and tested for co-segregation, meaning that the variant had to be present in affected relatives and absent in unaffected ones across each pedigree, exactly as an autosomal dominant disease gene would predict.

The search paid off. Nine distinct POU4F3 variants were identified across nine families, and four of them had never been described before: a duplication designated c.149_152dup, two small deletions called c.687_688delCA and c.709_710delTC, and a single-letter substitution, c.704 C greater than T. The remaining five variants, including c.371 C greater than A, c.592 C greater than A, c.706 C greater than T, c.952 G greater than A, and a deletion spanning the end of exon 1 and the start of exon 2, had been reported previously. All variants were classified according to the guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, the internationally accepted framework for judging whether a genetic variant is pathogenic.

Perhaps the most striking statistic is the fraction of families explained by this one gene. POU4F3 variants accounted for 10.8 percent of the cohort, or nine of 83 families. The authors compared this with figures from selected European, Japanese, and Korean cohorts, which reported 6.5 percent, 2.5 percent, and 2.4 percent respectively. They were careful, however, to caution that such direct comparisons should be interpreted conservatively, because differences in how patients are recruited, which testing strategies are used, and the nature of the referral settings can all inflate or deflate apparent prevalence. Even so, the message is clear: in Chinese patients with familial progressive hearing loss, POU4F3 deserves a prominent place on any diagnostic gene panel.

Among the 35 confirmed variant carriers in the study, penetrance was complete, meaning every individual carrying a pathogenic variant showed clinical hearing loss at some point. The audiometric profile followed a characteristic pattern: predominantly mid-to-high-frequency sensorineural hearing loss that worsened with age. Cross-sectional analysis across the families revealed a gradient, with younger carriers showing milder, high-frequency impairment, often invisible in everyday conversation, while older individuals had progressed to severe-to-profound broadband loss affecting virtually all frequencies. This age-dependent progression is a hallmark of many dominant deafness genes and underscores why extended high-frequency audiometry, which tests frequencies above the standard clinical range, was an essential tool in the study, catching early damage that conventional pure-tone audiometry would miss.

Tinnitus, the perception of sound without an external source, emerged as a surprisingly informative companion symptom. Sixty percent of affected individuals, 21 of 35, reported subjective tinnitus. More remarkable still, 45 percent of those assessed for timing, nine of 20, developed tinnitus before any measurable hearing loss could be detected on an audiogram, with lead times ranging from zero to 27 years. In practical terms, a young adult from one of these families who begins to experience persistent ringing in the ears may be perceiving the earliest distress signals of dying or malfunctioning cochlear hair cells, decades before a standard hearing test would flag a problem. The authors propose that the triad of familial non-syndromic hearing loss, progressive sloping sensorineural loss, and accompanying tinnitus could serve as a practical clinical clue to trigger earlier genetic evaluation, though they emphasize that this framework requires prospective validation.

The study also explored how different classes of variants shape the clinical picture. Exploratory genotype-phenotype analysis suggested that truncating variants, those that introduce a premature stop signal and chop the Brn-3c protein short, may be associated with earlier onset and more severe hearing loss, consistent with the idea that a nonfunctional protein causes a loss of protective function in hair cells. Missense variants, which substitute a single amino acid, showed greater phenotypic variability, particularly when they fell within the protein’s core DNA-binding domains, the POU-specific and homeobox regions that grip target genes and regulate their expression. The authors integrated their nine variants with 43 previously published ones to build these correlations, and compiled literature and ClinVar data identifying 82 pathogenic or likely pathogenic POU4F3 variants worldwide, of which 59, or 72 percent, were associated with East Asian reports. They note that this apparent geographic concentration may partly reflect ascertainment and reporting practices rather than true population genetics alone.

The clinical implications extend beyond diagnosis. As gene therapy for inherited deafness moves from concept to clinic, with several trials targeting other deafness genes already underway, knowing which gene underlies a patient’s condition becomes the gateway to future precision treatment. Identifying POU4F3 carriers early, ideally through the tinnitus-first presentation described here, would allow families to receive accurate genetic counseling, understand the roughly 50 percent transmission risk to each child of a carrier, plan monitoring schedules with extended high-frequency audiometry, and position themselves for intervention as therapies mature. The study was approved by the Medical Ethics Committee of Chinese PLA General Hospital and funded by China’s National Key R&D Program and the National Natural Science Foundation of China.

For now, the researchers urge that POU4F3 be prioritized within hearing-loss gene panels, particularly for Chinese and East Asian patients presenting with compatible phenotypes. The work also carries a broader lesson for auditory medicine: symptoms that patients often dismiss as a minor nuisance, a faint ringing after a loud concert or a persistent hum in quiet rooms, can be the first audible thread in a genetic story that unfolds over decades. Listening carefully to tinnitus, and pairing it with family history and modern sequencing, may allow clinicians to catch hereditary hearing loss at its very beginning, when the window for preserving hearing, and eventually for repairing it, is widest.

Subject of Research: Prevalence and clinical characteristics of POU4F3 gene variants in Chinese patients with autosomal dominant non-syndromic hearing loss and tinnitus

Article Title: POU4F3 variants are prevalent in Chinese patients with autosomal dominant non-syndromic hearing loss and concurrent tinnitus

Article References: Zhang, Q., Zeng, L., Wang, R., Lu, Y., Wu, X., Balan, V., Zhang, L., Chen, G., Xie, L., Zhang, Y., Guo, F., Ning, F., Wang, D., Han, D., Yuan, H., & Wang, Q. (2026). POU4F3 variants are prevalent in Chinese patients with autosomal dominant non-syndromic hearing loss and concurrent tinnitus. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08915-3

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08915-3

Keywords: POU4F3, DFNA15, hearing loss, tinnitus, autosomal dominant, genetics, whole-exome sequencing, sensorineural hearing loss, genotype-phenotype correlation, East Asian population, genetic counseling, cochlear hair cells